Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2017 by Marijn E. Dekkers, Novalis LifeSciences LLC is based in the United States and specializes in the life sciences sector. The firm manages $500 million across three funds, focusing on both venture capital and private equity investments. Novalis also offers business advisory services through Novalis Advisory.
Novalis LifeSciences invests in life science tools, diagnostics, and biopharma therapeutics, targeting companies at pre-seed through Series C stages. The firm provides funding ranging from early-stage investments to later-stage growth capital, supporting a diverse range of life science innovations.
Notable portfolio companies include Cerevel Therapeutics, acquired by AbbVie in August 2024; Decipher Biosciences, acquired by Veracyte in March 2021; and Celsee, acquired by Bio-Rad in April 2020. Other significant investments include Ginkgo Bioworks, public since September 2021, and Quanterix, public since December 2017.
Submit your pitch through their form at novalislifesciences.com.
Yes, Novalis LifeSciences often leads investment rounds, particularly in early-stage companies within their focus sectors.
The firm is open to follow-on investments, especially for companies that demonstrate strong growth potential and align with their investment thesis.
Novalis LifeSciences manages a total of $500 million across three funds dedicated to life sciences investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.